Provided by Tiger Trade Technology Pte. Ltd.

SINO BIOPHARM

6.600
+0.1201.85%
Volume:51.70M
Turnover:343.17M
Market Cap:123.82B
PE:30.55
High:6.720
Open:6.520
Low:6.520
Close:6.480
52wk High:9.120
52wk Low:2.890
Shares:18.76B
HK Float Shares:18.76B
Volume Ratio:0.75
T/O Rate:0.28%
Dividend:0.09
Dividend Rate:1.42%
EPS(LYR):0.216
ROE:15.40%
ROA:5.07%
PB:3.29
PE(LYR):30.55
PS:3.59

Loading ...

Sino Biopharmaceutical Stock Rallies 1.9% in Hong Kong, Outperforms Competitors

Dow Jones
·
23 mins ago

BUZZ-Sino Biopharm climbs most in five weeks on cancer drug development progress

Reuters
·
2 hours ago

SINO BIOPHARM (01177): Patient Enrollment Completed for Phase III Trial of Claudiximab "CLDN18.2 ADC"

Stock News
·
10 hours ago

Sino Biopharmaceutical (1177) Announces Completion of Phase III Enrollment for Tecotabart Vedotin “CLDN18.2 ADC”

Bulletin Express
·
10 hours ago

Sino Biopharmaceutical Completes Phase III Enrollment for Tecotabart Vedotin in Gastric Cancer

Reuters
·
10 hours ago

Assessing Sino Biopharmaceutical’s Valuation After Positive TQA3605 Phase II Hepatitis B Trial Results

Simply Wall St.
·
Yesterday

Sino Biopharmaceutical Stock Slides 5.3% in Hong Kong, Underperforms Competitors

Dow Jones
·
Feb 02

Sino Biopharmaceutical Stock Falls 3.3% in Hong Kong

Dow Jones
·
Jan 30

Sino Biopharmaceutical Stock Climbs 2.4% in Hong Kong

Dow Jones
·
Jan 28

Sino Biopharmaceutical Hepatitis B Drug Meets Primary Goal of Phase 2 Study

MT Newswires Live
·
Jan 27

Sino Biopharmaceutical Limited (1177) Announces Positive Phase II Results for TQA3605 "Core Protein Allosteric Modulator" in Chronic Hepatitis B

Bulletin Express
·
Jan 27

Sino Biopharmaceutical Reports Positive Phase II Results for Hepatitis B Drug TQA3605

Reuters
·
Jan 27

Sino Biopharmaceutical Stock Slides 1.7% in Hong Kong

Dow Jones
·
Jan 26

Sino Biopharmaceutical Stock Advances 2.0% in Hong Kong, Outperforms Competitors

Dow Jones
·
Jan 23

Sino Biopharmaceutical Stock Rises 1.1% in Hong Kong

Dow Jones
·
Jan 21

Sino Biopharmaceutical Stock Slips 6.2% in Hong Kong, Underperforms Competitors

Dow Jones
·
Jan 19

Citigroup: SINO BIOPHARM (01177) Acquisition of siRNA Firm Enhances Out-Licensing Potential; Sets Target Price at HK$10.8, "Buy" Rating

Stock News
·
Jan 16

CICC Maintains "Outperform" Rating on Sino Biopharm (01177) with HK$8.9 Target Price

Stock News
·
Jan 15

Sino Biopharmaceutical Stock Slides 1.5% in Hong Kong, Underperforms Competitors

Dow Jones
·
Jan 15

Sino Biopharmaceutical Stock Rises 2.9% in Hong Kong, Outperforms Competitors

Dow Jones
·
Jan 14